MICAL-Like 1 (MICALL1) Peptide
MICALL1
Reactivité: Humain
Hôte: Synthetic
BP, IHC, WB
-
- Antigène Tous les produits MICAL-Like 1 (MICALL1)
- MICAL-Like 1 (MICALL1)
- Origine
- Humain
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Immunohistochemistry (IHC), Western Blotting (WB)
- Attributs du produit
- This is a synthetic peptide designed for use in combination with anti-MICALL1 antibody (Catalog #: ARP51692_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- Purification
- Purified
-
-
- Indications d'application
- Each Investigator should determine their own optimal working dilution for specific applications.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Concentration
- 1 mg/mL
- Buffer
- Final peptide concentration is 1 mg/mL in PBS.
- Conseil sur la manipulation
- Avoid repeated freeze-thaw cycles.
- Stock
- -20 °C
- Stockage commentaire
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Antigène
- MICAL-Like 1 (MICALL1)
- Synonymes
- mirab13 Peptide, mical-l1 Peptide, MICAL-L1 Peptide, MIRAB13 Peptide, 260 Peptide, AI448246 Peptide, D15Mit260 Peptide, D15N2e Peptide, EST573322 Peptide, EST820961 Peptide, MIRab13 Peptide, mKIAA1668 Peptide, MICAL like 1 Peptide, microtubule associated monooxygenase, calponin and LIM domain containing -like 1 Peptide, MICALL1 Peptide, micall1 Peptide, Micall1 Peptide
- Sujet
-
MICALL1 contains 1 CH (calponin-homology) domain and 1 LIM zinc-binding domain. It may be a cytoskeletal regulator.
Alias Symbols: DKFZp686M2226, FLJ45921, KIAA1668, MICAL-L1, MIRAB13
Protein Interaction Partner: RAB1A,YWHAB,YWHAG,PACSIN1,PACSIN2,PACSIN3
Protein Size: 863 - Poids moléculaire
- 93 kDa
- ID gène
- 85377
- NCBI Accession
- NM_033386, NP_203744
- UniProt
- Q8N3F8
-
Vous êtes ici:
